Format
Items per page
Sort by

Send to:

Choose Destination

Results: 18

Related Articles by Review for PubMed (Select 21712452)

1.

Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.

Weniger MA, Rizzatti EG, Pérez-Galán P, Liu D, Wang Q, Munson PJ, Raghavachari N, White T, Tweito MM, Dunleavy K, Ye Y, Wilson WH, Wiestner A.

Clin Cancer Res. 2011 Aug 1;17(15):5101-12. doi: 10.1158/1078-0432.CCR-10-3367. Epub 2011 Jun 28.

2.

Dissecting bortezomib: development, application, adverse effects and future direction.

Cao B, Li J, Mao X.

Curr Pharm Des. 2013;19(18):3190-200. Review.

PMID:
23151134
3.

Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.

Leonard JP, Furman RR, Coleman M.

Int J Cancer. 2006 Sep 1;119(5):971-9. Review.

PMID:
16557600
4.

Proteasome inhibition in the treatment of cancer.

Richardson PG, Mitsiades C, Hideshima T, Anderson KC.

Cell Cycle. 2005 Feb;4(2):290-6. Epub 2005 Feb 3. Review.

5.

Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP.

Curr Cancer Drug Targets. 2011 Mar;11(3):239-53. Review.

6.

Novel proteasome inhibitors to overcome bortezomib resistance.

Ruschak AM, Slassi M, Kay LE, Schimmer AD.

J Natl Cancer Inst. 2011 Jul 6;103(13):1007-17. doi: 10.1093/jnci/djr160. Epub 2011 May 23. Review.

7.

Advances in the understanding of mechanisms and therapeutic use of bortezomib.

Mujtaba T, Dou QP.

Discov Med. 2011 Dec;12(67):471-80. Review.

8.

The role of bortezomib in the treatment of lymphoma.

Barr P, Fisher R, Friedberg J.

Cancer Invest. 2007 Dec;25(8):766-75. Review.

PMID:
18058474
9.
10.

Proteasome inhibitors in mantle cell lymphoma.

Holkova B, Grant S.

Best Pract Res Clin Haematol. 2012 Jun;25(2):133-41. doi: 10.1016/j.beha.2012.04.007. Epub 2012 May 16. Review.

11.

Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.

Bogner C, Peschel C, Decker T.

Leuk Lymphoma. 2006 Feb;47(2):195-205. Review.

PMID:
16321849
12.

Bortezomib in mantle cell lymphoma.

Suh KS, Goy A.

Future Oncol. 2008 Apr;4(2):149-68. doi: 10.2217/14796694.4.2.149. Review.

PMID:
18407730
13.

Bortezomib for the treatment of non-Hodgkin's lymphoma.

Bose P, Batalo MS, Holkova B, Grant S.

Expert Opin Pharmacother. 2014 Nov;15(16):2443-59. doi: 10.1517/14656566.2014.965142. Epub 2014 Sep 29. Review.

PMID:
25263936
14.

Treatment of mantle cell lymphoma: targeting the microenvironment.

Drach J, Seidl S, Kaufmann H.

Expert Rev Anticancer Ther. 2005 Jun;5(3):477-85. Review.

PMID:
16001955
15.

Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatment.

Montagut C, Rovira A, Mellado B, Gascon P, Ross JS, Albanell J.

Drugs Today (Barc). 2005 May;41(5):299-315. Review.

PMID:
16082428
16.

Proteasome inhibitors in the treatment of B-cell malignancies.

Schenkein D.

Clin Lymphoma. 2002 Jun;3(1):49-55. Review.

PMID:
12141956
17.

From bortezomib to other inhibitors of the proteasome and beyond.

Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP.

Curr Pharm Des. 2013;19(22):4025-38. Review.

18.

New molecular targets in mantle cell lymphoma.

Parekh S, Weniger MA, Wiestner A.

Semin Cancer Biol. 2011 Nov;21(5):335-46. doi: 10.1016/j.semcancer.2011.09.008. Epub 2011 Sep 18. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk